Choline C-11
Choline C-11 was the first PET tracer approved in the United States, in 2012, to find where prostate cancer has come back when PSA rises after treatment; PSMA tracers have now largely replaced it.
Overview
The FDA approved Choline C 11 Injection in September 2012, produced at the Mayo Clinic, for PET imaging of patients with suspected prostate cancer recurrence and non-informative bone scan, CT or MRI, the first approval of a PET agent for prostate cancer. Its 20-minute half-life means it must be made on site with a cyclotron, which confined it to a few centres. From 2020 the PSMA-targeted tracers gallium-68 PSMA-11 and piflufolastat F-18, with higher sensitivity at low PSA and longer half-lives, took over most recurrence imaging, and fluciclovine F-18 offered a distributable amino-acid alternative.
- Detector ring
- Tracer uptake
- 511 keV photon pair
1.Choline C-11 slips into a pocket on its target.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2012 | PET imaging of suspected prostate cancer recurrence with non-informative conventional imaging |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Choline C-11" OR ABSTRACT:"Choline C-11" OR TITLE:"Choline C 11 Injection" OR ABSTRACT:"Choline C 11 Injection" OR TITLE:"[11C]choline" OR ABSTRACT:"[11C]choline") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Choline C-11, not a curated reading list.
Similar pages
not linked directly; found by shared links- AgentPSMA-1007 F-18
Shares PET (positron emission tomography), PSMA PET, Fluorine-18, Gallium-68.
- TrialInvestigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Shares PET (positron emission tomography), Gallium-68, Prostate cancer.
- TrialThis Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
Shares PET (positron emission tomography), Gallium-68, Prostate cancer.
- PersonThomas A. Hope
Shares PET (positron emission tomography), PSMA PET, Gallium-68, Prostate cancer.
- PersonJohannes Czernin
Shares PET (positron emission tomography), PSMA PET, Gallium-68, Prostate cancer.
- TrialBiodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Shares PET (positron emission tomography), Gallium-68, Prostate cancer.
- TrialStudy of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares PET (positron emission tomography), Fluorine-18, Prostate cancer.
- TrialTest-retest Evaluation of [18F]F-AraG PET